Researchers have developed an innovative dual-receptor T-cell therapy that promises safer and more effective cancer ...

OmRx Oncology begins phase 2 trial of oral PD-L1 inhibitor OX-4224 in patients with non-small cell lung cancer: San Diego Saturday, May 10, 2025, 12:00 Hrs [IST] OmRx Oncology, or ...

A Ludwig Cancer Research study has identified a key mechanism by which advanced ovarian cancers suppress anti-tumor immune ...

An evaluation of nearly 19,000 patients with metastatic colorectal cancer supported clinical trial data that immunotherapy ...

Onctura commences randomized Phase I/II study in non-small cell lung cancer First patient dosed in study investigating roginolisib + dostarlimab +/- docetaxel in patients with NSCLC who have ...

Patients older than 65 years had similar clinical outcomes in response to immune checkpoint inhibitors as younger patients with cancer.

Patients who were positive for cytomegalovirus had more immune cells circulating in their blood before they started ...

Despite a risk for severe side effects, pembrolizumab has a record of improving recurrence-free survival that makes it an appealing treatment for advanced melanoma.

Cryptic peptides, which are expressed in pancreatic cancer cells, could be promising targets for T-cell therapies that attack pancreatic tumors, according to a new study.

This Research Topic is the second volume of the “Immune Responses Against Tumors - From the Bench to the Bedside” Community Series. Please see Volume I ...

OmRx Oncology (OmRx) has commenced a Phase II trial for its OX-4224, targeting individuals with non-small cell lung cancer ...

Discovery of innate immune receptor "brake" Siglec-E offers a novel therapeutic target to prevent organ transplant rejection ...